Supera支架治疗复杂股腘动脉病变的疗效:真实世界证据的短期结果分析
这项回顾性研究收集了2019年1月至2022年3月间治疗的162例复杂股腘动脉病变患者的治疗与随访数据,分为非Supera支架组、Supera支架组和Supera支架+药物涂层球囊(DCB)组。12个月一期通畅率非Supera组为47.6%,Supera组为58.7%,Supera+DCB组为60.0%,组间无显著差异;Supera组12个月免于靶病变血运重建的Rutherford分级改善优于非Supera组(73.3% vs 54.8%,P=0.041)。作者认为Supera支架在复杂外周动脉疾病中显示出有效性和安全性,但联合DCB未提供显著优势,需在更大患者人群中进一步研究验证。
要点
- 12个月一期通畅率:非Supera组47.6%、Supera组58.7%、Supera+DCB组60.0%,组间无显著差异。
- 全因死亡、靶肢体大截肢和靶病变血运重建组间无显著差异。
- Supera组12个月免于靶病变血运重建的Rutherford分级改善优于非Supera组(73.3% vs 54.8%,P=0.041)。
核心结论
- Supera支架在治疗复杂外周动脉疾病中显示出有效性和安全性,但Supera支架联合DCB未提供显著优势。
- 作者指出需在更大患者人群中进一步研究以验证这些发现。
研究设计与样本
- 回顾性研究,收集2019年1月至2022年3月间治疗的复杂股腘动脉病变患者的治疗与随访数据。
- 共纳入162例患者,分为非Supera支架组、Supera支架组和Supera支架+DCB组。
- 主要有效性结局为12个月一期通畅率,定义为12个月随访时双功能超声收缩期峰值流速比<2.5。
主要发现
- 12个月一期通畅率:非Supera组47.6%,Supera组58.7%,Supera+DCB组60.0%,组间无显著差异。
- 全因死亡、靶肢体大截肢和靶病变血运重建组间无显著差异。
- 12个月免于靶病变血运重建的Rutherford分级改善:Supera组73.3% vs 非Supera组54.8%(P=0.041)。
- 12个月随访时超过65%的患者维持Rutherford分级3级或以下,Supera组中74.7%的患者有轻度症状。
局限性
- 原文指出需在更大患者人群中进一步研究以验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: When dealing with complex femoropopliteal lesions, there is a growing preference for the utilization of drug-coated balloons (DCBs) or stents. However, in real-world scenarios, a greater number of elderly patients with longer lesion lengths are encountered. The purpose of our study was to compare the efficacy and safety of different interventional strategies, including the utilization of Supera stent and DCB, in a real-world setting. METHODS: This was a retrospective study that collected treatment and follow-up data of patients with complex femoropopliteal artery lesions treated between January 2019 and March 2022. All patients were categorized into 3 groups: "non-Supera stent group," "Supera stent group," and "Supera stent + DCB group." The primary effectiveness outcome was primary patency at 12 months, defined as duplex ultrasound peak systolic velocity ratio < 2.5 at the 12-month visit. Other outcomes included improvements in Rutherford categories and safety. RESULTS: A total of 162 patients were enrolled in this study. Compared with non-Supera group (47.6%) in the primary patency rate at 12 months, Supera group (58.7%) or Supera + DCB group (60.0%) showed no significant difference. There were no significant differences in all-cause death, major amputation of the target limb, and target lesion revascularization between the groups. Supera group showed a significant improvement in Rutherford category without target lesion revascularization at 12 months compared with non-Supera group (73.3% vs. 54.8%, P = 0.041). In 12-month follow-up, more than 65% of patients maintained a Rutherford category of 3 or in the following, particularly in Supera group where 74.7% of patients had mild symptoms. CONCLUSIONS: The Supera stent has demonstrated its efficacy and safety in treating complex peripheral artery disease. However, combining Supera stent with DCB did not provide a significant advantage. Furthermore research is necessary to validate these findings in a larger patient population.
引用
- Tang X, Ma H, Zhou G, et al. Efficacy of Supera Stent in the Treatment of Complex Femoropopliteal Artery Lesions: A Short-Term Result Analysis of Real-World Evidence. Ann Vasc Surg. 2024. PMID: 39032594. doi:10.1016/j.avsg.2024.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。